The U.S FDA has approved Rinvoq® (upadacitinib – AbbVie) to treat active ankylosing spondylitis (AS) in adults who have an inadequate response or intolerance to one or more tumor necrosis factor blockers.

• AS is a chronic inflammatory disease that can cause bones in the spine to fuse together. Rinvoq, which first received FDA approval in 2019, is also indicated to treat rheumatoid arthritis, active psoriatic arthritis, and moderate to severe ulcerative colitis.
• The recommended dose to treat AS is 15mg of Rinvoq taken by mouth once daily.